BRCA1 and ovarian cancer: Finally, NGS-based testing of all coding exons in both genes may be reserved for patients with breast or ovarian cancer that is more likely related to BRCA. These considerations for the comprehensive assessment of pathogenic mutations in breast and ovarian cancers are exemplified for BRCA1 C1501X mutation found in multiple family members during conducting this study (Table 5 and Additional file 2).